NCT02390375View on ClinicalTrials.gov

Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

348

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

May 31, 2016

Conditions
Hypercholesterolemia
Interventions
DRUG

DW-0929

5/10mg

DRUG

DW-0929

10/10mg

DRUG

DW-0929

20/10mg

DRUG

Rosuvastatin

5mg F/U study: DW-0929 5/10mg

DRUG

Rosuvastatin

10mg F/U study: DW-0929 10/10mg

DRUG

Rosuvastatin

20mg F/U study: DW-0929 20/10mg

Trial Locations (1)

156-707

Boramae Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewon Pharmaceutical Co., Ltd.

INDUSTRY

NCT02390375 - Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia | Biotech Hunter | Biotech Hunter